Premium
Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer
Author(s) -
Omari Aleksandra,
Nastały Paulina,
Stoupiec Sara,
Bałabas Aneta,
Dąbrowska Michalina,
Bielińska Beata,
Huss Sebastian,
Pantel Klaus,
Semjonow Axel,
Eltze Elke,
Brandt Burkhard,
BednarzKnoll Natalia
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31905
Subject(s) - prostate cancer , cancer research , vimentin , metastasis , cancer , pathological , tumor progression , tumor suppressor gene , oncology , biology , pathology , medicine , immunohistochemistry , carcinogenesis
BRCA1 is a pivotal tumor suppressor. Its dysfunction is known to play a role in different tumors. Among others, BRCA1 germline mutations account for higher risk and more aggressive course of prostate cancer (PCa). In addition, somatic BRCA1 gene loss was demonstrated to be a signature of PCa dissemination to lymph nodes and peripheral blood, and indicate worse clinical outcome. In order to substantiate the data for BRCA1 gene loss in PCa and reveal its phenotypical background, BRCA1 gene status was assessed in a large cohort of PCa patients and compared to different molecular factors. BRCA1 gene dosage was assessed in 2398 tumor samples from 1,199 PCa patients using fluorescent in situ hybridization. It was compared to clinico‐pathological parameters, patients’ outcome as well as selected proteins (Ki‐67, apoptosis marker, cytokeratins, vimentin, E‐ and N‐cadherin, ALDH1 and EGFR) examined immunohistochemically. BRCA1 losses were found in 10%, whereas gains appeared in 7% of 603 informative PCa patients. BRCA1 losses correlated to higher T stage ( p = 0.027), Gleason score ( p = 0.039), shorter time to biochemical recurrence in patients with Gleason score > 7 independently of other factors (multivariate analysis, p = 0.005) as well as expression of proteins regulating stemness and epithelial‐mesenchymal transition, that is, ALDH1 ( p = 0.021) and EGFR ( p = 0.011), respectively. BRCA1 gains correlated to shorter time to metastasis ( p = 0.012) and expression of ALDH1 ( p = 0.014). These results support the assumption that BRCA1 gene losses contribute to a progressive and stem cell‐like phenotype of PCa. Furthermore, they reveal that also BRCA1 gain conceivably representing loss‐of‐function might mark more invasive tumors.